Immune-Mediated Disorders Causing Bleeding or Thrombosis in Lymphoproliferative Diseases

Abstract

Bleeding and thrombosis are important complications in patients with malignant lymphomas. They may be due to direct actions of the lymphoma, such as venous compression or bone marrow infiltration, but they may also be caused by paraneoplastic phenomena, which are immune-mediated in most of the cases. The most important paraneoplastic immune-mediated disorders in lymphomas causing bleeding are autoimmune thrombocytopenia, acquired hemophilia A and acquired von Willebrand syndrome. In addition, there are a variety of other less common immune-mediated bleeding conditions, such as acquired thrombasthenia, acquired factor X-, V-, XI-, XII-, or prothrombin deficiency. The presence of antiphospholipid antibodies is a rare condition predisposing to venous and arterial thrombosis and there are other very uncommon conditions, which predispose exclusively to arterial thrombosis such as hyperlipidemic xanthomatosis. Interestingly, there is hardly any correlation between the histological type and the aggressiveness of lymphoma and the type and prevalence of the immune-mediated conditions. Successful treatment of the underlying lymphoma is often associated with definite and sustained resolution of the immune-mediated disorder.

Keywords

lymphoma - autoimmune complications - thrombosis - bleeding - treatment

• References

• 1 Swerdlow SH, Campo E, Harris NL , et al. WHO Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008
• 2 Rossi D, De Paoli L, Franceschetti S , et al. Prevalence and clinical characteristics of immune thrombocytopenic purpura in a cohort of monoclonal gammopathy of uncertain significance. Br J Haematol 2007; 138 (2) 249-252
• 3 Bida JP, Kyle RA, Therneau TM , et al. Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients. Mayo Clin Proc 2009; 84 (8) 685-693
• 4 Knoebl P, Marco P, Baudo F , et al; EACH2 Registry Contributors. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost 2012; 10 (4) 622-631
• 5 Moreno C, Hodgson K, Ferrer G , et al. Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood 2010; 116 (23) 4771-4776
• 6 Visco C, Ruggeri M, Laura Evangelista M , et al. Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood 2008; 111 (3) 1110-1116
• 7 Shvidel L, Tadmor T, Braester A , et al; Israeli CLL Study Group (ICLLSG). Pathogenesis, prevalence, and prognostic significance of cytopenias in chronic lymphocytic leukemia (CLL): a retrospective comparative study of 213 patients from a national CLL database of 1,518 cases. Ann Hematol 2013; 92 (5) 661-667
• 8 Barcellini W, Capalbo S, Agostinelli RM , et al; GIMEMA Chronic Lymphocytic Leukemia Group. Relationship between autoimmune phenomena and disease stage and therapy in B-cell chronic lymphocytic leukemia. Haematologica 2006; 91 (12) 1689-1692
• 9 Ansell P, Simpson J, Lightfoot T , et al. Non-Hodgkin lymphoma and autoimmunity: does gender matter?. Int J Cancer 2011; 129 (2) 460-466
• 10 Thieblemont C, Davi F, Noguera ME , et al. Splenic marginal zone lymphoma: current knowledge and future directions. Oncology (Williston Park) 2012; 26 (2) 194-202 (Williston Park)
• 11 Owen RG, Lubenko A, Savage J, Parapia LA, Jack AS, Morgan GJ. Autoimmune thrombocytopenia in Waldenström's macroglobulinemia. Am J Hematol 2001; 66 (2) 116-119
• 12 Kyrtsonis MC, Vassilakopoulos TP, Angelopoulou MK , et al. Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit. Ann Hematol 2001; 80 (12) 722-727
• 13 Jønsson V, Kierkegaard A, Salling S , et al. Autoimmunity in Waldenström's macroglobulinaemia. Leuk Lymphoma 1999; 34 (3–4) 373-379
• 14 Hivert B, Caron C, Petit S , et al. Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia. Blood 2012; 120 (16) 3214-3221
• 15 Bairey O, Blickstein D, Monselise Y , et al. Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin's lymphoma. Eur J Haematol 2006; 76 (5) 384-391
• 16 Auwerda JJ, Sonneveld P, de Maat MP, Leebeek FW. Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma. Haematologica 2007; 92 (2) 279-280
• 17 Choufani EB, Sanchorawala V, Ernst T , et al. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood 2001; 97 (6) 1885-1887
• 18 Váróczy L, Páyer E, Kádár Z , et al. Malignant lymphomas and autoimmunity-a single center experience from Hungary. Clin Rheumatol 2012; 31 (2) 219-224
• 19 Dimou M, Angelopoulou MK, Pangalis GA , et al. Autoimmune hemolytic anemia and autoimmune thrombocytopenia at diagnosis and during follow-up of Hodgkin lymphoma. Leuk Lymphoma 2012; 53 (8) 1481-1487
• 20 Mahipal A, Bilgrami S. Acquired hemophilia in chronic lymphocytic leukemia. Leuk Lymphoma 2007; 48 (5) 1026-1028
• 21 Sallah S, Wan JY. Inhibitors against factor VIII associated with the use of interferon-alpha and fludarabine. Thromb Haemost 2001; 86 (4) 1119-1121
• 22 Endo T, Yatomi Y, Amemiya N , et al. Antibody studies of factor VIII inhibitor in a case with Waldenström's macroglobulinemia. Am J Hematol 2000; 63 (3) 145-148
• 23 Gesierich W, Munker R, Geiersberger U, Pohlmann H, Brack N, Hartenstein R. Spontaneous Bleeding in a Patient with Malignant Lymphoma: A Case of Acquired Hemophilia. Onkologie 2000; 23 (6) 584-588
• 24 Wenz B, Friedman G. Acquired factor VIII inhibitor in a patient with malignant lymphoma. Am J Med Sci 1974; 268 (5) 295-299
• 25 Ohtaka A, Muroi K, Izumi T , et al. Severe bleeding in a case of factor VIII inhibitor associated with intravascular lymphomatosis [in Japanese]. Rinsho Ketsueki 1993; 34 (2) 194-199
• 26 Casas E, García Puig J, Villar A, González Sanz A, Miranda ME, Ortiz Vázquez J. Hemorrhagic syndrome associated with a factor VIII:C inhibitor in a patient with lymphoma [in Spanish]. Med Clin (Barc) 1989; 93 (1) 23-25
• 27 Bendandi M, Zaccaria A, Zinzani PL , et al. Factor VIII inhibitor prior to and during secondary acute nonlymphocytic leukemia in a patient with cured Hodgkin's disease. Leuk Lymphoma 1995; 16 (5-6) 511-513
• 28 Marietta M, Pozzi S, Luppi M , et al. Acquired haemophilia in HIV negative, HHV-8 positive multicentric Castleman's disease: a case report. Eur J Haematol 2003; 70 (3) 181-182
• 29 Tiplady CW, Hamilton PJ, Galloway MJ. Acquired haemophilia complicating the remission of a patient with high grade non-Hodgkin's lymphoma treated by fludarabine. Clin Lab Haematol 2000; 22 (3) 163-165
• 30 Gouault-Heilmann M, Dumont MD, Intrator L, Chenal C, Lejonc JL. Acquired von Willebrand's syndrome with IgM inhibitor against von Willebrand's factor. J Clin Pathol 1979; 32 (10) 1030-1035
• 31 Stewart AK, Glynn MF. Acquired von Willebrand disease associated with free lambda light chain monoclonal gammopathy, normal bleeding time and response to prednisone. Postgrad Med J 1990; 66 (777): 560-562
• 32 van Genderen PJ, Vink T, Michiels JJ, van 't Veer MB, Sixma JJ, van Vliet HH. Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen. Blood 1994; 84 (10) 3378-3384
• 33 Federici AB, Rand JH, Bucciarelli P , et al; Subcommittee on von Willebrand Factor. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 2000; 84 (2) 345-349
• 34 Kumar S, Pruthi RK, Nichols WL. Acquired von Willebrand's syndrome: a single institution experience. Am J Hematol 2003; 72 (4) 243-247
• 35 Mayerhofer M, Haushofer A, Kyrle PA , et al. Mechanisms underlying acquired von Willebrand syndrome associated with an IgM paraprotein. Eur J Clin Invest 2009; 39 (9) 833-836
• 36 Lamboley V, Zabraniecki L, Sie P, Pourrat J, Fournié B. Myeloma and monoclonal gammopathy of uncertain significance associated with acquired von Willebrand's syndrome. Seven new cases with a literature review. Joint Bone Spine 2002; 69 (1) 62-67
• 37 Kos CA, Ward JE, Malek K , et al. Association of acquired von Willebrand syndrome with AL amyloidosis. Am J Hematol 2007; 82 (5) 363-367
• 38 Castaman G, Federici AB, Tosetto A , et al. Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients. J Thromb Haemost 2012; 10 (4) 632-638
• 39 Tiede A, Rand JH, Budde U, Ganser A, Federici AB. How I treat the acquired von Willebrand syndrome. Blood 2011; 117 (25) 6777-6785
• 40 Federici AB, Stabile F, Castaman G, Canciani MT, Mannucci PM. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood 1998; 92 (8) 2707-2711
• 41 Friederich PW, Wever PC, Briët E, Doorenbos CJ, Levi M. Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease. Am J Hematol 2001; 66 (4) 292-294
• 42 Mannucci PM, Kyrle PA, Schulman S, Di Paola J, Schneppenheim R, Gill JC. Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor/factor VIII concentrate in adults and children with von Willebrand's disease undergoing elective surgery: a pooled and comparative analysis of data from USA and European Union clinical trials. Blood Transfus 2013; 11 (4) 533-540
• 43 Ojeda-Uribe M, Caron C, Itzhar-Baikian N, Debliquis A. Bortezomib effectiveness in one patient with acquired von Willebrand syndrome associated to monoclonal gammopathy of undetermined significance. Am J Hematol 2010; 85 (5) 396
• 44 Grimaldi D, Bartolucci P, Gouault-Heilmann M, Martin-Toutain I, Khellaf M, Godeau B. Rituximab failure in a patient with monoclonal gammopathy of undetermined significance (MGUS)-associated acquired von Willebrand syndrome. Thromb Haemost 2008; 99 (4) 782-783
• 45 Biondo F, Matturro A, Santoro C , et al. Remission of acquired von Willebrand syndrome after successful treatment of gastric MALT lymphoma. Haemophilia 2012; 18 (1) e34-e35
• 46 Iwabuchi T, Kimura Y, Suzuki T , et al. Successful treatment with rituximab in a patient with primary thymic MALT lymphoma complicated with acquired von Willebrand syndrome and Sjögren syndrome [in Japanese]. Rinsho Ketsueki 2011; 52 (4) 210-215
• 47 Kanakry JA, Gladstone DE. Maintaining hemostasis in acquired von Willebrand syndrome: a review of intravenous immunoglobulin and the importance of rituximab dose scheduling. Transfusion 2013; 53 (8) 1730-1735
• 48 Cuker A, Connors JM, Katz JT, Levy BD, Loscalzo J. Clinical problem-solving. A bloody mystery. N Engl J Med 2009; 361 (19) 1887-1894
• 49 Slattery W, Rausch D, Saba N. Refractory acquired von Willebrand disease despite successful treatment of the associated lymphoma. Mayo Clin Proc 2002; 77 (12) 1391
• 50 Silberstein LE, Abrahm J, Shattil SJ. The efficacy of intensive plasma exchange in acquired von Willebrand's disease. Transfusion 1987; 27 (3) 234-237
• 51 Morris ES, Hampton KK, Nesbitt IM, Preston FE, Thomas EG, Makris M. The management of von Willebrand's disease-associated gastrointestinal angiodysplasia. Blood Coagul Fibrinolysis 2001; 12 (2) 143-148
• 52 Brown C, Subramanian V, Wilcox CM, Peter S. Somatostatin analogues in the treatment of recurrent bleeding from gastrointestinal vascular malformations: an overview and systematic review of prospective observational studies. Dig Dis Sci 2010; 55 (8) 2129-2134
• 53 Nomikou E, Tsevrenis V, Gafou A, Bellia M, Theodossiades G. Type IIb von Willebrand disease with angiodysplasias and refractory gastrointestinal bleeding successfully treated with thalidomide. Haemophilia 2009; 15 (6) 1340-1342
• 54 Lupu A, Stefanescu C, Treton X, Attar A, Corcos O, Bouhnik Y. Bevacizumab as rescue treatment for severe recurrent gastrointestinal bleeding in hereditary hemorrhagic telangiectasia. J Clin Gastroenterol 2013; 47 (3) 256-257
• 55 Joist JH, Cowan JF, Zimmerman TS. Acquired von Willebrand's disease. Evidence for a quantitative and qualitative factor VIII disorder. N Engl J Med 1978; 298 (18) 988-991
• 56 Tran-Thang C, Mannucci PM, Schneider P, Federici A, Bachmann F. Profound alterations of the multimeric structure of von Willebrand factor in a patient with malignant lymphoma. Br J Haematol 1985; 61 (2) 307-314
• 57 Siaka C, Rugeri L, Caron C, Goudemand J. A new ELISA assay for diagnosis of acquired von Willebrand syndrome. Haemophilia 2003; 9 (3) 303-308
• 58 Mohri H, Motomura S, Kanamori H , et al. Clinical significance of inhibitors in acquired von Willebrand syndrome. Blood 1998; 91 (10) 3623-3629 Erratum in: Blood 1999 Jan 1;93(1):413
• 59 Handin RI, Martin V, Moloney WC. Antibody-induced von Willebrand's disease: a newly defined inhibitor syndrome. Blood 1976; 48 (3) 393-405
• 60 Sampson BM, Greaves M, Malia RG, Preston FE. Acquired von Willebrand's disease: demonstration of a circulating inhibitor to the factor VIII complex in four cases. Br J Haematol 1983; 54 (2) 233-244
• 61 Mohri H, Hisanaga S, Mishima A, Fujimoto S, Uezono S, Okubo T. Autoantibody inhibits binding of von Willebrand factor to glycoprotein Ib and collagen in multiple myeloma: recognition sites present on the A1 loop and A3 domains of von Willebrand factor. Blood Coagul Fibrinolysis 1998; 9 (1) 91-97
• 62 Schwarzinger I, Stain-Kos M, Bettelheim P , et al. Recurrent, isolated factor X deficiency in myeloma: repeated normalization of factor X levels after cytostatic chemotherapy followed by late treatment failure associated with the development of systemic amyloidosis. Thromb Haemost 1992; 68 (6) 648-651
• 63 Nicholson JA, Tappin J. Raccoon eyes in systemic AL amyloidosis. Br J Haematol 2011; 153 (5) 543
• 64 Oran B, Wright DG, Seldin DC, McAneny D, Skinner M, Sanchorawala V. Spontaneous rupture of the spleen in AL amyloidosis. Am J Hematol 2003; 74 (2) 131-135
• 65 Dispenzieri A, Seenithamby K, Lacy MQ , et al. Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center. Bone Marrow Transplant 2013; 48 (10) 1302-1307
• 66 Sanchorawala V, Wright DG, Seldin DC , et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 2001; 28 (7) 637-642
• 67 Levin M, Chokas W. Acquired factor X deficiency and amyloidosis treated with melphalan and prednisone. N Engl J Med 1987; 317 (18) 1155-1156
• 68 Greipp PR, Kyle RA, Bowie EJ. Factor X deficiency in primary amyloidosis: resolution after splenectomy. N Engl J Med 1979; 301 (19) 1050-1051
• 69 Gertz MA. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment. Am J Hematol 2013; 88 (5) 416-425
• 70 Alamelu J, McCormick A, Moore GW, Madan B. Acquired prothrombin deficiency in a patient with follicular lymphoma. Haemophilia 2008; 14 (3) 634-636
• 71 Lee ES, Hibsman BK, Liebman HA. Acquired bleeding disorder in a patient with malignant lymphoma: antibody-mediated prothrombin deficiency. Cancer 2001; 91 (4) 636-641
• 72 Rochanda L, Del Zoppo GJ, Feinstein DI, Liebman HA. Approach to the treatment, characterization and diagnosis of an acquired auto-antibody directed against factors prothrombin, factor X and factor IX: a case report and review of the literature. Haemophilia 2012; 18 (1) 102-107
• 73 Hurtubise PE, Coots MC, Jacob DJ, Muhleman AF, Glueck HI. A monoclonal IgG4 (lambda) with factor V inhibitory activity. J Immunol 1979; 122 (5) 2119-2121
• 74 Grigg AP, Dauer R, Thurlow PJ. Bleeding due to an acquired inhibitor of platelet associated factor V. Aust N Z J Med 1989; 19 (4) 310-314
• 75 van Spronsen DJ, Oosting JD, Hoffmann JJ, Breed WP. Factor V inhibitor associated with cold agglutinin disease. Ann Hematol 1998; 76 (1) 49-50
• 76 Emori Y, Sakugawa M, Niiya K , et al. Life-threatening bleeding and acquired factor V deficiency associated with primary systemic amyloidosis. Blood Coagul Fibrinolysis 2002; 13 (6) 555-559
• 77 Tosetto A, Rodeghiero F, Gatto E, Manotti C, Poli T. An acquired hemorrhagic disorder of fibrin crosslinking due to IgG antibodies to FXIII, successfully treated with FXIII replacement and cyclophosphamide. Am J Hematol 1995; 48 (1) 34-39
• 78 Goodrick MJ, Prentice AG, Copplestone JA, Pamphilon DH, Boon RJ. Acquired factor XI inhibitor in chronic lymphocytic leukaemia. J Clin Pathol 1992; 45 (4) 352-353
• 79 Gastineau DA, Gertz MA, Daniels TM, Kyle RA, Bowie EJ. Inhibitor of the thrombin time in systemic amyloidosis: a common coagulation abnormality. Blood 1991; 77 (12) 2637-2640
• 80 Colwell NS, Tollefsen DM, Blinder MA. Identification of a monoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder. Br J Haematol 1997; 97 (1) 219-226
• 81 Zent CS, Ding W, Reinalda MS , et al. Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. Leuk Lymphoma 2009; 50 (8) 1261-1268
• 82 D'Arena G, Capalbo S, Laurenti L , et al. Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients. Eur J Haematol 2010; 85 (6) 502-507
• 83 Rossignol J, Michallet AS, Oberic L , et al. Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia. Leukemia 2011; 25 (3) 473-478
• 84 Al-Nawakil C, Park S, Chapuis N , et al. Salvage therapy of autoimmune thrombocytopenic purpura revealing non-Hodgkin lymphoma by the thrombopoietin receptor agonist romiplostim. Br J Haematol 2012; 156 (1) 145-147
• 85 D'Arena G, Cascavilla N. Romiplostim for chronic lymphocytic leukemia-associated immune thrombocytopenia. Leuk Lymphoma 2011; 52 (4) 701-704
• 86 Gudbrandsdottir S, Frederiksen H, Hasselbalch H. Thrombopoietin-receptor agonists in haematological disorders: the Danish experience. Platelets 2012; 23 (6) 423-429
• 87 Koehrer S, Keating MJ, Wierda WG. Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP. Leukemia 2010; 24 (5) 1096-1098
• 88 Jennings NS, Harmer IJ, Campbell K , et al. Molecular characterization of the variable domains of an alphaIIbbeta3-specific immunoglobulin M kappa platelet cold agglutinin in a follicular lymphoma patient with treatment refractory autoimmune thrombocytopenia: idiotypic overlap between alphaIIbbeta3 integrin antibodies. Transfusion 2007; 47 (3) 499-510
• 89 Lehman HA, Lehman LO, Rustagi PK , et al. Complement-mediated autoimmune thrombocytopenia. Monoclonal IgM antiplatelet antibody associated with lymphoreticular malignant disease. N Engl J Med 1987; 316 (4) 194-198
• 90 Nobuoka A, Sakamaki S, Kogawa K , et al. A case of malignant lymphoma producing autoantibody against platelet glycoprotein Ib. Int J Hematol 1999; 70 (3) 200-206
• 91 Noda M, Mori N, Nomura K , et al. Regression of idiopathic thrombocytopenic purpura after endoscopic mucosal resection of gastric mucosa associated lymphoid tissue lymphoma. Gut 2004; 53 (11) 1698-1700
• 92 Yamamoto E, Ozaki N, Nakagawa M, Kimoto M. Primary bilateral adrenal lymphoma associated with idiopathic thrombocytopenic purpura. Leuk Lymphoma 1999; 35 (3-4) 403-408
• 93 Moriwaki Y, Naka M, Yamamoto T , et al. Malignant lymphoma in the mesentery with immune thrombocytopenia. Intern Med 1992; 31 (10) 1185-1189
• 94 Landgren O, Engels EA, Pfeiffer RM , et al. Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst 2006; 98 (18) 1321-1330
• 95 Lechner K, Chen YA. Paraneoplastic autoimmune cytopenias in Hodgkin lymphoma. Leuk Lymphoma 2010; 51 (3) 469-474
• 96 McMillan R, Bowditch RD, Tani P, Anderson H, Goodnight S. A non-thrombocytopenic bleeding disorder due to an IgG4-kappa anti-GPIIb/IIIa autoantibody. Br J Haematol 1996; 95 (4) 747-749
• 97 DiMinno G, Coraggio F, Cerbone AM , et al. A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder. J Clin Invest 1986; 77 (1) 157-164
• 98 Porcelijn L, Huiskes E, Maatman R, de Kreuk A, de Haas M. Acquired Glanzmann's thrombasthenia caused by glycoprotein IIb/IIIa autoantibodies of the immunoglobulin G1 (IgG1), IgG2 or IgG4 subclass: a study in six cases. Vox Sang 2008; 95 (4) 324-330
• 99 Giannini S, Mezzasoma AM, Guglielmini G, Rossi R, Falcinelli E, Gresele P. A new case of acquired Glanzmann's thrombasthenia: diagnostic value of flow cytometry. Cytometry B Clin Cytom 2008; 74 (3) 194-199
• 100 Balduini CL, Grignani G, Sinigaglia F , et al. Severe platelet dysfunction in a patient with autoantibodies against membrane glycoproteins IIb-IIIa. Haemostasis 1987; 17 (1-2) 98-104
• 101 Malik U, Dutcher JP, Oleksowicz L. Acquired Glanzmann's thrombasthenia associated with Hodgkin's lymphoma: a case report and review of the literature. Cancer 1998; 82 (9) 1764-1768
• 102 Kubota T, Tanoue K, Murohashi I , et al. Autoantibody against platelet glycoprotein IIb/IIIa in a patient with non-Hodgkin's lymphoma. Thromb Res 1989; 53 (4) 379-386
• 103 Tholouli E, Hay CR, O'Gorman P, Makris M. Acquired Glanzmann's thrombasthenia without thrombocytopenia: a severe acquired autoimmune bleeding disorder. Br J Haematol 2004; 127 (2) 209-213
• 104 Akashi K, Shibuya T, Taniguchi S , et al. Multiple autoimmune haemopoietic disorders and insidious clonal proliferation of large granular lymphocytes. Br J Haematol 1999; 107 (3) 670-673
• 105 Füreder W, Mitterbauer G, Thalhammer R , et al. Clonal T cell-mediated cyclic thrombocytopenia. Br J Haematol 2002; 119 (4) 1059-1061
• 106 Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med 2013; 368 (11) 1033-1044
• 107 Lechner K, Simonitsch I, Haselböck J, Jäger U, Pabinger I. Acquired immune-mediated thrombophilia in lymphoproliferative disorders. Leuk Lymphoma 2011; 52 (10) 1836-1843
• 108 Garcia D, Akl EA, Carr R, Kearon C. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood 2013; 122 (5) 817-824
• 109 Hsieh K, Knöbl P, Rintelen C , et al. Is the determination of anti-beta2 glycoprotein I antibodies useful in patients with venous thromboembolism without the antiphospholipid syndrome?. Br J Haematol 2003; 123 (3) 490-495
• 110 Wahl DG, Guillemin F, de Maistre E, Perret-Guillaume C, Lecompte T, Thibaut G. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus 1998; 7 (1) 15-22
• 111 Caruso V, Di Castelnuovo A, Meschengieser S , et al. Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events. Blood 2010; 115 (26) 5322-5328
• 112 de Laat B, Derksen RH, Urbanus RT, de Groot PG. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005; 105 (4) 1540-1545
• 113 Coloma Bazán E, Donate López C, Moreno Lozano P, Cervera R, Espinosa G. Discontinuation of anticoagulation or antiaggregation treatment may be safe in patients with primary antiphospholipid syndrome when antiphospholipid antibodies became persistently negative. Immunol Res 2013; 56 (2-3) 358-361
• 114 Bazzan M, Montaruli B, Vaccarino A, Fornari G, Saitta M, Prandoni P. Presence of low titre of antiphospholipid antibodies in cancer patients: a prospective study. Intern Emerg Med 2009; 4 (6) 491-495
• 115 Abramson JS, Chatterji M, Rahemtullah A. Case records of the Massachusetts General Hospital. Case 39-2008. A 51-year-old woman with splenomegaly and anemia. N Engl J Med 2008; 359 (25) 2707-2718
• 116 Manner H, Jung B, Tonassi L , et al. Successful treatment of catastrophic antiphospholipid antibody syndrome (CAPS) associated with splenic marginal-zone lymphoma with low-molecular weight heparin, rituximab and bendamustine. Am J Med Sci 2008; 335 (5) 394-397
• 117 Murakami H, Irisawa H, Saitoh T , et al. Immunological abnormalities in splenic marginal zone cell lymphoma. Am J Hematol 1997; 56 (3) 173-178
• 118 Sawamura M, Yamaguchi S, Murakami H , et al. Multiple autoantibody production in a patient with splenic lymphoma. Ann Hematol 1994; 68 (5) 251-254
• 119 Voinchet H, Etienne G, Ghiringelli CB , et al. Splenic marginal zone lymphoma and autoimmunity: report of six cases [in French]. Rev Med Interne 2010; 31 (1) 4-11
• 120 Keung YK, Cobos E, Meyerrose GE, Roberson GH. Progressive thrombosis after treatment of diffuse large cell non-Hodgkin's lymphoma and concomitant lupus anticoagulant. Leuk Lymphoma 1996; 20 (3-4) 341-345
• 121 Shaw BE, Perry D, Hoffbrand AV. Progressive arterial thrombosis in a patient with non-Hodgkin's lymphoma, a lupus anticoagulant, factor V Leiden mutation and paraprotein, following chemotherapy. Leuk Lymphoma 2001; 42 (1-2) 221-223
• 122 Stefani PM, Pietrogrande F, Sartori R, Girolami A. Immunosuppression due to MACOP-B does not seem to cure the antiphospholipid syndrome. Haematologica 1999; 84 (8) 751-752
• 123 Colović N, Miljić P, Colović M, Milosević-Jovcić N. Multiple M components in two patients with splenic lymphoma with villous lymphocytes. Ann Hematol 2006; 85 (1) 51-54
• 124 Erre GL, Pardini S, Faedda R, Passiu G. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus 2008; 17 (1) 50-55
• 125 Asherson RA. The catastrophic antiphospholipid (Asherson's) syndrome. Autoimmun Rev 2006; 6 (2) 64-67
• 126 Shapira I, Andrade D, Allen SL, Salmon JE. Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum 2012; 64 (8) 2719-2723
• 127 Mazodier K, Arnaud L, Mathian A , et al. Lupus anticoagulant-hypoprothrombinemia syndrome: report of 8 cases and review of the literature. Medicine (Baltimore) 2012; 91 (5) 251-260
• 128 Hara Y, Makita M, Ishikawa T , et al. Lupus anticoagulant hypoprothrombinemia syndrome in Bence-Jones protein κ-type multiple myeloma patient with phosphatidylserine-dependent antiprothrombin antibody. Ann Hematol 2013; 92 (4) 563-564
• 129 Kim KJ, Baek IW, Yoon CH, Kim WU, Cho CS. Thrombotic risk in patients with immune thrombocytopenia and its association with antiphospholipid antibodies. Br J Haematol 2013; 161 (5) 706-714
• 130 Stasi R, Stipa E, Masi M , et al. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood 1994; 84 (12) 4203-4208
• 131 Liebman HA. Recognizing and treating secondary immune thrombocytopenic purpura associated with lymphoproliferative disorders. Semin Hematol 2009; 46 (1) (Suppl. 02) S33-S36
• 132 Pullarkat V, Ngo M, Iqbal S, Espina B, Liebman HA. Detection of lupus anticoagulant identifies patients with autoimmune haemolytic anaemia at increased risk for venous thromboembolism. Br J Haematol 2002; 118 (4) 1166-1169
• 133 Davidson SJ, Burman JF, Nicholson AG, Jones DW, Dusmet ME. Factor XII auto-antibodies present in a patient with a B-cell lymphoma. Blood Coagul Fibrinolysis 2005; 16 (5) 365-367
• 134 Gruber A, Blaskó G, Sas G. Functional deficiency of protein C and skin necrosis in multiple myeloma. Thromb Res 1986; 42 (4) 579-581
• 135 Miljić P, Milosević-Jovicić N, Antunović P, Bosković D, Basara N, Rolović Z. Recurrent venous thrombosis in a patient with chronic lymphocytic leukemia and acquired protein S deficiency. Haematologia (Budap) 2000; 30 (1) 51-54
• 136 Deitcher SR, Erban JK, Limentani SA. Acquired free protein S deficiency associated with multiple myeloma: a case report. Am J Hematol 1996; 51 (4) 319-323
• 137 El Kababri M, El Khorassani M, Hessissen L , et al. Non-Hodgkin's lymphoma with protein S deficiency [in French]. Arch Pediatr 2004; 11 (1) 29-32
• 138 Schwartz J, Gonzalez J, Rosenberg R , et al. Cutaneous T-cell lymphoma, tropical spastic paraparesis, cerebral vasculitis, and protein S deficiency in a patient with HTLV-I. South Med J 1996; 89 (10) 999-1000
• 139 Lechner K, Obermeier HL. Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Medicine (Baltimore) 2012; 91 (4) 195-205
• 140 Kawahara M, Kanno M, Matsumoto M, Nakamura S, Fujimura Y, Ueno S. Diffuse neurodeficits in intravascular lymphomatosis with ADAMTS13 inhibitor. Neurology 2004; 63 (9) 1731-1733
• 141 Simonelli S, Gianazza E, Mombelli G , et al. Severe high-density lipoprotein deficiency associated with autoantibodies against lecithin:cholesterol acyltransferase in non-Hodgkin lymphoma. Arch Intern Med 2012; 172 (2) 179-181
• 142 Ohashi N, Aomatsu M, Mori A , et al. Intravascular lymphoma with extremely low high-density lipoproteinemia. Intern Med 2007; 46 (17) 1475-1477
• 143 Szalat R, Arnulf B, Karlin L , et al. Pathogenesis and treatment of xanthomatosis associated with monoclonal gammopathy. Blood 2011; 118 (14) 3777-3784
• 144 Misselwitz B, Goede JS, Pestalozzi BC, Schanz U, Seebach JD. Hyperlipidemic myeloma: review of 53 cases. Ann Hematol 2010; 89 (6) 569-577
• 145 Sykes DB, Schroyens W, O'Connell C. The TEMPI syndrome—a novel multisystem disease. N Engl J Med 2011; 365 (5) 475-477
• 146 Kwok M, Korde N, Landgren O. Bortezomib to treat the TEMPI syndrome. N Engl J Med 2012; 366 (19) 1843-1845
• 147 Schroyens W, O'Connell C, Sykes DB. Complete and partial responses of the TEMPI syndrome to bortezomib. N Engl J Med 2012; 367 (8) 778-780
• 148 Hauswirth AW, Skrabs C, Schützinger C , et al. Autoimmune thrombocytopenia in non-Hodgkin's lymphomas. . Haematologica 2008; 93 (3) 447-450
• 149 Shinagawa A, Kojima H, Kobayashi T, Kawada K, Nagasawa T. Lupus anticoagulant-like activity observed in a dimeric lambda protein produced by myeloma cells. Int J Hematol 2001; 73 (4) 526-531
• 150 Regina S, Colombat P, Fimbel B, Guerois C, Gruel Y. Acquired inhibitor to factor VIII in a patient with Hodgkin's disease following treatment with interferon-alpha. Haemophilia 2001; 7 (5) 526-527
• 151 Castaldi PA, Penny R. A macroglobulin with inhibitory activity against coagulation factor VIII. Blood 1970; 35 (3) 370-376
• 152 Kelsey PR, Leyland MJ. Acquired inhibitor to human factor VIII associated with paraproteinaemia and subsequent development of chronic lymphatic leukaemia. Br Med J (Clin Res Ed) 1982; 285 (6336) 174-175
• 153 Longo G, Luppi M, Ferrara L, Torelli U, Barbieri U, Torelli G. Acquired factor VIII inhibitor at the onset of prolymphocytic leukemia. Leukemia 1996; 10 (9) 1557-1558
• 154 Nakazaki K, Hangaishi A, Nakamura F , et al. IgG-associated immune thrombocytopenia in Waldenström macroglobulinemia. Int J Hematol 2010; 92 (2) 360-363
• 155 Richard C, Cuadrado MA, Prieto M , et al. Acquired von Willebrand disease in multiple myeloma secondary to absorption of von Willebrand factor by plasma cells. Am J Hematol 1990; 35 (2) 114-117
• 156 Collins P, Baudo F, Knoebl P , et al; EACH2 registry collaborators. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood 2012; 120 (1) 47-55
• 157 Tengborn L, Baudo F, Huth-Kühne A , et al; EACH2 registry contributors. Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry. BJOG 2012; 119 (12) 1529-1537